Fresenius Kabi, of Bad Homburg, Germany, supplies the Amicus and LOVO apheresis devices that collect and process cells for cell therapy, a large portfolio of generic chemotherapy injectables, biosimilars and infusion products. Its generics have filled gaps during injectable shortages, which keep recurring because the economics of generic injectables remain unfixed.
Fresenius Kabi, based in Bad Homburg and part of Fresenius SE, supplies apheresis devices including Amicus and LOVO, generic oncology injectables, biosimilars and infusion products. Its large generic chemotherapy portfolio and cell-processing devices have made it a key source during injectable shortages. OnCo links it to apheresis and starting-material collection, generic oncology drug supply and shortage mitigation, and infusion pumps and ambulatory chemotherapy devices. Whether the economics of generic injectables can be fixed so that shortages stop recurring is the open question. The drug shortage technology page carries the wider picture.
Shares Generic oncology drug supply and shortage mitigation, Generic sterile injectables (the 2023 platinum shortage) and the tag supporting.
Shares Apheresis and starting-material collection and the tag supporting.
Shares Infusion pumps, ports, and ambulatory chemotherapy devices and the tag supporting.
Shares Infusion pumps, ports, and ambulatory chemotherapy devices and the tag supporting.
Shares Infusion pumps, ports, and ambulatory chemotherapy devices and the tag supporting.
Shares Generic oncology drug supply and shortage mitigation, Generic sterile injectables (the 2023 platinum shortage) and the tag supporting.
Shares Apheresis and starting-material collection and the tag supporting.
Shares Infusion pumps, ports, and ambulatory chemotherapy devices and the tag supporting.